# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

\_\_\_\_\_

#### FORM 8-K

# CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 24, 2024
OrthoPediatrics Corp.

(Exact name of registrant as specified in its charter)

#### Delaware

(State or other jurisdiction of incorporation)

**001-38242** (Commission File Number)

26-1761833

(I.R.S. Employer Identification Number)

2850 Frontier Drive Warsaw, Indiana (Address of principal executive offices)

46582

(Zip Code)

Name of each exchange on which registered

Nasdaq Global Market

Registrant's telephone number, including area code: (574) 268-6379

#### Not Applicable

(Former name or former address, if changed since last report)

Trading Symbol(s)

KIDS

Securities registered pursuant to Section 12(b) of the Act:

**Title of Each Class** 

Common Stock, \$0.00025 par value per share

Check t	the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Exchang	e by check mark whether the registrant is an emerging growth company as defined in Rule 405 under the Securities Act (17 CFR 230.405) or Rule 12b-2 under the ge Act (17 CFR 240.12b-2).
Emergir	ng growth company □
	merging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised al accounting standards provided pursuant to Section 13(a) of the Exchange Act

### Item 5.07. Submission of Matters to a Vote of Security Holders.

On May 24, 2024, OrthoPediatrics Corp. (the "Company") held its 2024 Annual Meeting of Stockholders and the Company's stockholders voted on the following matters:

#### Election of Directors

The nominees below were elected to serve as directors for a term that will last until the Company's 2027 Annual Meeting of Stockholders or until his or her successor is duly elected and qualified. The number of votes cast for and withheld from each nominee and the number of broker non-votes with respect to each nominee were as follows:

Name	Votes For	<b>Votes Withheld</b>	<b>Broker Non-Votes</b>
David R. Bailey	18,199,037	1,790,600	727,703
Marie C. Infante	12,686,531	7,186,996	843,813
Jimmy D. McDonald	14,265,857	5,721,728	729,755

Approval, on an advisory basis, of the compensation of the Company's named executive officers

The Company's stockholders approved the compensation of the Company's named executive officers by voting as follows:

For	Against	Abstain	<b>Broker Non-Votes</b>
19,430,742	258,906	304,480	723,212

Approval of the OrthoPediatrics Corp. 2024 Incentive Award Plan

The Company's stockholders approved the OrthoPediatrics Corp. 2024 Incentive Award Plan by voting as follows:

For	Against	Abstain	<b>Broker Non-Votes</b>
18,409,907	1,279,054	305,167	723,212

Approval, on an advisory basis, of the appointment of Deloitte & Touche LLP as the Company's Independent Registered Public Accounting Firm for our Fiscal Year Ending December 31, 2024

The Company's stockholders approved the appointment by the Audit Committee of the Company's Board of Directors of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024 by voting as follows:

For	Against	Abstain
20,565,406	150,366	1,568

\*\*\*\*\*

### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OrthoPediatrics Corp.

Date: May 28, 2024 By: /s/ Daniel J. Gerritzen

Daniel J. Gerritzen, General Counsel and Secretary